1. Home
  2. NCL vs RNAZ Comparison

NCL vs RNAZ Comparison

Compare NCL & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northann Corp.

NCL

Northann Corp.

HOLD

Current Price

$0.17

Market Cap

7.7M

Sector

N/A

ML Signal

HOLD

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$8.74

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCL
RNAZ
Founded
2013
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
8.5M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
NCL
RNAZ
Price
$0.17
$8.74
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$280.00
AVG Volume (30 Days)
662.9K
609.3K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,997,205.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$6.08
52 Week High
$12.16
$399.00

Technical Indicators

Market Signals
Indicator
NCL
RNAZ
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NCL
RNAZ

About NCL Northann Corp.

Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

Share on Social Networks: